N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
NCT ID: NCT01265563
Last Updated: 2018-10-19
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
108 participants
INTERVENTIONAL
2011-01-31
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Antioxidant Treatment of Type 2 Diabetes
NCT00609102
The Impact of Vitamins and Minerals Supplementation on Neuropathy and Nephropathy Complications
NCT01173315
Oxidative Stress, Carbohydrate Metabolism Disorders and G6PD Deficiency
NCT05571748
Glutathione-rich Foods for Type 2 Diabetes
NCT04386187
The Effects of Micronutrients in Combination With Usual Care in Type 2 Diabetes
NCT01738802
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study intends to test the hypothesis that combined oral supplementation of the antioxidants N-acetylcysteine (NAC) and milk thistle flavonolignan silibin (as silibin-phosphatidylcholine) will reduce proteinuria and urinary and systemic manifestations of oxidative stress and inflammation, which are characteristically observed in patients with T2DM and related nephropathy. The investigators expect these effects to be achieved with minimal or no side effects, and with good patient tolerance.
The trial is designed as a two-center, double-blind, placebo-controlled, randomized, modified-factorial dose-ranging design, five-arm pilot study in patients with Type 2 diabetes mellitus and advanced diabetic nephropathy with proteinuria.
Intervention consists of three-month oral administration of NAC, silibin, and/or respective placebos for three months. Subjects are randomized to the following five intervention arms: (A) placebo; (B) NAC; (C) silibin; (D) NAC + silibin; and (E) NAC + double-dose silibin.
The primary outcome measure is urinary excretion of albumin, a marker of glomerular injury. Secondary outcome measures are alpha-1 microglobulin, a marker of tubular injury, and urinary excretion of inflammatory cytokines and C-C chemokines, i.e. markers of renal inflammation. In addition, peripheral blood monocytes from the same patients are analyzed for GSH content and activity of GSH metabolizing enzymes. All outcome measures are monitored in relation to both treatment allocation and prevalent blood and urine levels of the active treatment. Safety and tolerability of this combination treatment are monitored throughout the trial.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NAC placebo and Silibin placebo
Drug: N-acetylcysteine placebo and Drug: Silibin placebo
N-acetylcysteine placebo and silibin placebo
Dietary Supplement: N-acetylcysteine placebo excipient and silibin placebo orally twice daily for three months
NAC active and Silibin placebo
Drug: N-acetylcysteine and Drug: Silibin placebo
N-acetylcysteine active and silibin placebo
Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin placebo orally twice a day for three months
NAC placebo and Silibin active
Drug: N-acetylcysteine placebo and Drug: Silibin active
N-acetylcysteine placebo and silibin active
Dietary Supplement: silibin 480 mg orally twice daily and N-acetylcysteine placebo orally twice a day for three months
NAC active and Silibin active
Drug: N-acetylcysteine active and Drug: Silibin active
N-acetylcysteine active and silibin active
Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 480 mg orally twice daily for three months
NAC active and High-dose Silibin active
Drug: N-acetylcysteine active and Drug: Silibin higher dose active
N-acetylcysteine active + high-dose silibin active
Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 960 mg orally twice daily for three months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
N-acetylcysteine placebo and silibin placebo
Dietary Supplement: N-acetylcysteine placebo excipient and silibin placebo orally twice daily for three months
N-acetylcysteine active and silibin placebo
Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin placebo orally twice a day for three months
N-acetylcysteine placebo and silibin active
Dietary Supplement: silibin 480 mg orally twice daily and N-acetylcysteine placebo orally twice a day for three months
N-acetylcysteine active and silibin active
Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 480 mg orally twice daily for three months
N-acetylcysteine active + high-dose silibin active
Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 960 mg orally twice daily for three months
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Type 2 diabetes mellitus
* Diabetic nephropathy, as defined by:
* estimated GFR between 60 and 15 ml/min
* presence of proteinuria
* Current medical treatment with low dose aspirin
* Treatment of hypertension with (but not limited to):
* one diuretic
* one beta-blocker
* and one medication from the classes Angiotensin Receptor Blockers (ARBs) or Angiotensin Converting Enzyme inhibitors (ACE-I)
* Treatment of hyperglycemia with (but not limited to) glipizide and the medication class insulin
* Treatment of hypercholesterolemia with (but not limited to) one medication from the class statins
Exclusion Criteria
* Glycosylated hemoglobin (HbA1C) \> 10%
* \>20% variation in estimated GFR, during last 6 months
* Systolic Blood Pressure \>170 mmHg or Diastolic Blood Pressure \>100 mmHg on medications
* Other secondary forms of hypertension (endocrine, renovascular)
* History of intolerance to:
* Both ACE-I and ARBs
* The investigational supplements
* Iodinated radiologic contrast material
* Known non diabetic renal disease
* or history of solid organ transplantation
* Hepatitis virus or Human Immunodeficiency virus infections
* Use of one of the following medications within 2 months prior to enrollment in the study:
* Metformin
* Thiazolidinediones (pioglitazone or rosiglitazone)
* Phenytoin
* Warfarin
* Prescription-grade vitamin E, vitamin C, systemic steroids, and/or non-steroidal anti-inflammatory agents
* Over-the-counter vitamin E, vitamin C, and/or non-steroidal anti-inflammatory agents
* Over-the-counter antioxidants supplements including:
* Lipoic acid
* Coenzyme Q10
* N-acetyl-cysteine (NAC)
* Glutathione (GSH)
* Chromium
* Fish-oil extracts (omega-3 fatty acids)
* Soy extracts (isoflavones)
* Milk thistle extract (silymarin)
* Green-tea preparations
* Pomegranate extracts
* Grape extracts
* Prickly pear extract
* Active coronary artery disease or cerebral vascular disease within 3 months prior to signing the informed consent
* Hepatic dysfunction as defined by abnormal total bilirubin or liver enzymes (ALT, AST) \>2 times upper limit of normal range
* Active malignancy
* History of drug or alcohol dependency
* Psychiatric or neurological condition, preventing aware consent to the study and/or adherence to the study protocol
* Unwillingness to practice birth control throughout the study
* Participation to another clinical study within 1 month prior to signing the informed consent form
* Planned move to outside the study area, surgery or radiographic studies utilizing iodine-based contrast material within the next one year
18 Years
76 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Center for Complementary and Integrative Health (NCCIH)
NIH
VA Office of Research and Development
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paolo Fanti, MD
Role: PRINCIPAL_INVESTIGATOR
South Texas Health Care System, San Antonio, TX
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
South Texas Health Care System, San Antonio, TX
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Debnath S, Thameem F, Alves T, Nolen J, Al-Shahrouri H, Bansal S, Abboud HE, Fanti P. Diabetic nephropathy among Mexican Americans. Clin Nephrol. 2012 Apr;77(4):332-44. doi: 10.5414/cn107487.
Giustarini D, Dalle-Donne I, Milzani A, Fanti P, Rossi R. Analysis of GSH and GSSG after derivatization with N-ethylmaleimide. Nat Protoc. 2013 Sep;8(9):1660-9. doi: 10.1038/nprot.2013.095. Epub 2013 Aug 1.
Khazim K, Giustarini D, Rossi R, Verkaik D, Cornell JE, Cunningham SE, Mohammad M, Trochta K, Lorenzo C, Folli F, Bansal S, Fanti P. Glutathione redox potential is low and glutathionylated and cysteinylated hemoglobin levels are elevated in maintenance hemodialysis patients. Transl Res. 2013 Jul;162(1):16-25. doi: 10.1016/j.trsl.2012.12.014. Epub 2013 Jan 17.
Cunningham SE, Verkaik D, Gross G, Khazim K, Hirachan P, Agarwal G, Lorenzo C, Matteucci E, Bansal S, Fanti P. Comparison of Nutrition Profile and Diet Record Between Veteran and Nonveteran End-Stage Renal Disease Patients Receiving Hemodialysis in Veterans Affairs and Community Clinics in Metropolitan South-Central Texas. Nutr Clin Pract. 2015 Oct;30(5):698-708. doi: 10.1177/0884533615575046. Epub 2015 Apr 21.
Fanti P, Giustarini D, Rossi R, Cunningham SE, Folli F, Khazim K, Cornell J, Matteucci E, Bansal S. Dietary Intake of Proteins and Calories Is Inversely Associated With The Oxidation State of Plasma Thiols in End-Stage Renal Disease Patients. J Ren Nutr. 2015 Nov;25(6):494-503. doi: 10.1053/j.jrn.2015.06.003. Epub 2015 Jul 31.
Giustarini D, Galvagni F, Orlandini M, Fanti P, Rossi R. Immediate stabilization of human blood for delayed quantification of endogenous thiols and disulfides. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Apr 15;1019:51-8. doi: 10.1016/j.jchromb.2016.02.009. Epub 2016 Feb 8.
Khazim K, Gorin Y, Cavaglieri RC, Abboud HE, Fanti P. The antioxidant silybin prevents high glucose-induced oxidative stress and podocyte injury in vitro and in vivo. Am J Physiol Renal Physiol. 2013 Sep 1;305(5):F691-700. doi: 10.1152/ajprenal.00028.2013. Epub 2013 Jun 26.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VA 1I01CX000264-01A2
Identifier Type: REGISTRY
Identifier Source: secondary_id
CLIN-004-10S
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.